Placebo practice trials: The best predictor of adherence readiness for HAART among drug users?

HIV Clinical Trials

Volumn 4, Issue 4, 2003, Pages 269-281

  Wagner, Glenn ^a  

^a RAND CORPORATION   (United States)

Author keywords

Adherence readiness; Drug users; Practice trials

Indexed keywords

AMPHETAMINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; COCAINE; DIAMORPHINE; PLACEBO;

ADULT; ARTICLE; CLINICAL OBSERVATION; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DEPENDENCE; DRUG USE; FEMALE; HEALTH PRACTITIONER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RATING SCALE; SCREENING TEST; SOCIOECONOMICS; SUBSTANCE ABUSE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PILOT PROJECTS; PLACEBOS; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0042566138     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/YVTR-T8EV-3TQ6-QAJC     Document Type: Article

References (50)

1. Palella F, et al. Declining morbidity and mortality among patients with advanced HIV infection. New Engl J Med. 1998;338:853-860.
2. Cohn DC, et al. Continued benefit from highly active antiretroviral therapy: trends in AIDS-related opportunistic illnesses in a public health care system, 1990-2001. In: Program and abstracts of the XIVth International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract ThOrC1443.
3. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
4. Bangsberg DR, Hecht FM, Charlebois E, Chesney M, Moss AR. Comparing objective methods of adherence assessment: electronic medication monitoring and unannounced pill count. AIDS Behav. 2001;5:275-281.
5. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33:1417-1423.
6. Mathews WC, et al. Predictors, prevalence, and therapeutic effect of early adherence after starting or changing antiretroviral therapy. AIDS Patient Care STDS. 2002;16:157-172.
7. McNabb J, et al. Adherence to highly active antiretroviral therapy predicts outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis. 2001;33:700-705.
8. Wagner GJ, Ghosh-Dastidar B. Electronic monitoring: adherence assessment or intervention? HIV Clin Trials. 2002;3:45-51.
9. Deeks S, Beatty G, Cohen PT, Grant R, Volberding P. Viral load and CD4 T cell changes in patients failing potent protease inhibitor therapy. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, IL. Abstract 419.
10. 3) or later? Evidence for greater effectiveness if started early. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, CA. Abstract 522.
11. Little SJ, Routy JP, Daar ES, et al. Antiretroviral drug susceptibility and response to initial therapy among recently HIV-infected subjects in North America. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, IL. Abstract 755.
12. Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO. Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med. 2001;7:1016-1020.
13. US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. Washington, DC; 2001.
14. Santolaria-Fernandez FJ. Nutritional assessment of drug addicts. Drug Alcohol Depend. 1995;38:11-18.
15. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS. 1999;13:1099-1107.
16. Mannheimer S, Hirsch W, El-Sadr W. The impact of the ALR™ alarm device on antiretroviral (AR) adherence among HIV-infected outpatients in Harlem. In: Program and abstracts of the 12th International AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 32325.
17. Wenger N, Gifford A, Liu H, et al. Patient characteristics and attitudes associated with antiretroviral adherence. In: Program and abstracts of the 6th Conference on Antiretrovirals and Opportunistic Infections; January 31-February 4, 1999; Chicago, IL.
18. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30:S171-S176.
19. Weidle PJ, Ganea CE, Ernst J, McGowan J, Irwin KL, Holberg SD. Multiple reasons for nonadherence to antiretroviral medications in an inner-city minority population: need for 6 multifaceted approach to improve adherence. In: Program and abstracts of the 12th International AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 32360.
20. Halkitis P, Remien RH, Parsons JT, Stirratt MJ. Factors related to protease inhibitor adherence among sexually active men-who-have-sex-with-men. In: Program and abstracts of the 12th International AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 60192.
21. Celentano DD, Vlahov D, Cohn S, Shadle V, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544-547.
22. Strathdee SA, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547-549.
23. Bangsberg DR, Hecht FM, Clague H, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26:435-442.
24. Gross R, Bilker WB, Friedman HM, Coyne JC, Strom BL. Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS. 2002;16:1835-1836.
25. Prochaska JO. Assessing how people change. Cancer. 1991;67:805-807.
26. Willey C, Redding C, Stafford J, et al. Stages of change for adherence with medication regimens for chronic disease: development and validation of a measure. Clin Ther. 2000;22:858-871.
27. Konkle-Parker DJ. A motivational intervention to improve adherence to treatment of chronic disease. J Am Acad Nurse Pract. 2001;13:61-68.
28. Dunbar-Jacob J. Contributions to patient adherence: Is it time to share the blame? Health Psychol. 1993;12(2):91-92.
29. Lerner BH, Gulick RM, Dubler NN. Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease. Ann Intern Med. 1998;129:573-578.
30. Wagner GJ, Kanouse DE. Measuring the usual care control in adherence intervention trials. In: Program and abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract WePeB5813.
31. Bangsberg DR, Hecht FM, Charlebois E, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357-366.
32. Wendel CS, Mohler MJ, Kroesen K, Ampel NM, Gifford AL, Coons J. Barriers to use of electronic adherence monitoring in an HIV clinic. Ann Pharmacother. 2001;35:1010-1015.
33. Spitzer RL, Williams JBW, Gibbon M. Structured Clinical Interview for DSM-IV. Washington, DC: American Psychiatric Press, 1995.
34. McLellan AT, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992;9:199-213.
35. Remien RH, El-Bassel N, Caballo-Dieguez A, et al. Assessment scales for the SMART Couples Project. 2000.
36. Stall R, Hoff C, Coates T, et al. Decisions to get HIV tested and to accept antiretroviral therapies among gay/bisexual men: implications for secondary prevention efforts. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:151-160.
37. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care. 2000;12:255-266.
38. Delis DC, Kramer JH, Kaplah E, et al. California Verbal Learning Test, Research Edition. Cleveland, OH: Psychological Corp.; 1983.
39. Army Individual Test Battery. Manual of Directions and Scoring. Washington, DC: War Department; 1944.
40. Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York: Psychological Corp.; 1981.
41. Heaton RK, Grant I, Matthews CG. Comprehensive Norms for an Expanded Halstead-Reitan Battery. Odessa, FL: Psychological Assessment Resources; 1992.
42. Norman MA, Evans JD, Miller SW, Heaton RK. Demographically corrected norms for the California Verbal Learning Test. J Clin Exp Neuropsychol. 2000;22:80-94.
43. Beck A, Beamsesderfer A. Assessment of depression: The depression inventory. In: Pichot P, ed. Psychological Measurements in Psychopharmacology. Basel: S. Karger; 1974:151-169.
44. Wagner GJ, Iguchi M, Schneider S, Scott J, Anderson D. Placebo practice trials: a tool to assess and improve adherence readiness. HIV Clin Trials. 2002;3:475-481.
45. Senecal C, Nouwen A, White D. Motivation and dietary self-care in adults with diabetes: Are self-efficacy and autonomous self-regulation complementary or competing constructs? Health Psychol. 2000;19:452-457.
46. Thompson M, Gold M, Sathasivam K, et al. Adherence and relationship to antiretroviral efficacy in the H.E.A.R.T. (NZTA4006) study. Presented at: XIII International AIDS Conference; July 9-14, 2000; Durban, South Africa.
47. Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology. 2002;59:1944-1950.
48. Gifford AG, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386-395.
49. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAiliffe TL. Patterns, correlates and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19:124-133.
50. Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001;2:38-45.